Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma

Iovance Biotherapeutics, Inc. announced that the US FDA accepted its Biologics License Application for Lifileucel, a tumor-infiltrating lymphocyte therapy, for patients with advanced melanoma.